Therapeutics News and Research

RSS

Research may shed light on what causes people to suffer from life-threatening anxiety disorders

New research at Rutgers University may help shed light on how and why nervous system changes occur and what causes some people to suffer from life-threatening anxiety disorders while others are better able to cope.

20 Aug 2013

Study shows superantigens produced by staph bacteria cause infective endocarditis and sepsis

University of Iowa researchers have discovered what causes the lethal effects of staphylococcal infective endocarditis - a serious bacterial infection of heart valves that kills approximately 20,000 Americans each year.

20 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

Pre-doctoral students receive International Student Research Fellowships from HHMI

The Howard Hughes Medical Institute has awarded two doctoral students from the Sackler School of Graduate Biomedical Sciences at Tufts University with 2013 International Student Research Fellowships. Seblewongel Asrat, from Ethiopia, studies the bacterium that causes Legionnaires' disease while Jennifer Nwankwo, from Nigeria, studies red blood cell dehydration in sickle cell disease.

17 Aug 2013

Increased caffeine intake may reduce fatty liver in people with NAFLD

Surprise! Your morning cup of tea or coffee may be doing more than just perking you up before work. An international team of researchers led by Duke-NUS Graduate Medical School (Duke-NUS) and the Duke University School of Medicine suggest that increased caffeine intake may reduce fatty liver in people with non-alcoholic fatty liver disease (NAFLD).

17 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

Sanford-Burnham, Pfizer collaborates to identify therapeutic targets for treating obesity, diabetes

Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that it has entered into a collaboration with Pfizer Inc. to identify new therapeutic targets for preventing and treating complications of obesity and diabetes.

14 Aug 2013

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.

14 Aug 2013

DNDi and Institut Pasteur Korea collaborates to spur fight against neglected diseases

A collaboration between the Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) to spur the fight against neglected diseases has been established.

14 Aug 2013

NIH awards $17M to research projects to investigate emerging field of exRNA

The National Institutes of Health announced today it will award $17 million this year for 24 research projects designed to improve scientists' understanding of a newly discovered type of cell-to-cell communication based on extracellular (outside the cell) RNA, also called exRNA.

14 Aug 2013

Three winners announced for biomedical engineering design competition in DEBUT challenge

...

13 Aug 2013

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Precision Therapeutics will proudly continue its dedicated support to the NOCC Pittsburgh Chapter's 13th Annual Walk to Break the Silence on Ovarian Cancer. Precision has been a strong supporter of the NOCC 5 Mile Run/5 Mile & 1 Mile walk for over five years, and once again expects a great number of its employees will join together in full force to walk alongside ovarian cancer patients and survivors to help strengthen the partnerships it has forged by supporting the very cancer patients that it strives to help.

13 Aug 2013

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, today reported financial results for the quarter and six months ended June 30, 2013 and announced presentations at an upcoming medical conference and upcoming investor conferences.

13 Aug 2013

Durin receives grant to expand novel blood test that can detect Parkinson's

The Michael J. Fox Foundation for Parkinson's Research has awarded Durin Technologies, Inc., a grant of $351,200 to expand the development of Durin's novel blood test that can detect the presence of Parkinson's disease.

13 Aug 2013

Prime Therapeutics selected as finalist for URAC's Health Care Consumer Engagement and Protection Awards

Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), was selected as a finalist for URAC's 2013 Best Practices in Health Care Consumer Engagement and Protection Awards. Prime was selected for its Controlled Substance Drug Utilization Review (DUR) program, which is part of the GuidedHealth® platform.

12 Aug 2013

Gene combination therapy repairs and prevents future damage of muscles caused by DMD

New research on two promising gene therapies suggests that combining them into one treatment not only repairs muscle damage caused by Duchenne muscular dystrophy, but also prevents future injury from the muscle-wasting disease.

12 Aug 2013

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.

8 Aug 2013

DNA mutation 'signature' identified in urinary tract cancers linked to birthwort herb

Genomic sequencing experts at Johns Hopkins partnered with pharmacologists at Stony Brook University to reveal a striking mutational signature of upper urinary tract cancers caused by aristolochic acid, a plant compound contained in herbal remedies used for thousands of years to treat a variety of ailments such as arthritis, gout and inflammation.

8 Aug 2013

Researchers develop nanoprobe technique to help treat fatal diseases more effectively

Researchers at the University of Southampton, in collaboration with colleagues at the University of Cambridge, have developed a technique to help treat fatal diseases more effectively.

8 Aug 2013

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

Therapeutics News and Research

Research may shed light on what causes people to suffer from life-threatening anxiety disorders

Study shows superantigens produced by staph bacteria cause infective endocarditis and sepsis

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Pre-doctoral students receive International Student Research Fellowships from HHMI

Increased caffeine intake may reduce fatty liver in people with NAFLD

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Sanford-Burnham, Pfizer collaborates to identify therapeutic targets for treating obesity, diabetes

Oraya Therapy Stereotactic Radiotherapy for treatment of wet AMDs now available at Optegra

DNDi and Institut Pasteur Korea collaborates to spur fight against neglected diseases

NIH awards $17M to research projects to investigate emerging field of exRNA

Three winners announced for biomedical engineering design competition in DEBUT challenge

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Intercept Pharmaceuticals reports financial results for Second quarter 2013

Durin receives grant to expand novel blood test that can detect Parkinson's

Prime Therapeutics selected as finalist for URAC's Health Care Consumer Engagement and Protection Awards

Gene combination therapy repairs and prevents future damage of muscles caused by DMD

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

DNA mutation 'signature' identified in urinary tract cancers linked to birthwort herb

Researchers develop nanoprobe technique to help treat fatal diseases more effectively

Targacept reports net loss of $12.4 million for Q2 2013

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News